Comparing Pimavanserin and Quetiapine for Psychosis in Parkinson's and Lewy Body Dementia
This study is comparing two approved medications, pimavanserin and quetiapine, to see which one works better at reducing psychosis (hallucinations and delusions) in people with Parkinson's disease (PD) or dementia with Lewy bodies (DLB). These conditions are sometimes grouped as Lewy body disease (LBD). Researchers want to find out if one medication leads to a greater improvement in these symptoms when used in a regular clinical setting. You might be able to join if you are a patient at the neurology clinic at UT Health San Antonio, have psychosis due to PD or DLB, and need to start an antipsychotic medication. The study will measure improvements in psychosis over 6 months. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 94 participants. Participants will be randomly assigned to receive either pimavanserin or quetiapine.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 6 months to measure changes in their symptoms.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparing Antipsychotic Medications in LBD Over Time
At a glance
Conditions
NCT05590637
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University Health System
San Antonio, Texasstudy coordinator listed
Recruiting
UT Health Science Center - San Antonio
San Antonio, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Sarah Horn, MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Neuropsychiatry Inventory Questionnaire (NPI-Q), Hallucinations + Delusions (H+D)Baseline to 6 months
Change in the Hallucinations + Delusions sub-score of the neuropsychiatric inventory questionnaire. Each NPI-Q item is scored by severity (1-3), and distress to caregiver (0-5), then added together (range 0-8) with a higher score indicating greater severity.